SOUTH SAN FRANCISCO, Calif., Oct.
21, 2020 /PRNewswire/ -- Akero
Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
biotechnology company developing transformational treatments for
patients with non-alcoholic steatohepatitis (NASH) and other
serious metabolic disorders, today announced that management will
present at the following investor conferences next month:
- 29th Annual Credit Suisse Healthcare Conference on
Monday, November 9th at
1:15PM EST
- Jefferies Global Healthcare Conference on Tuesday, November 17th at 1:45PM EST
A live webcast of each presentation and Q&A will be
available through the investor relations section of the Company's
website at www.akerotx.com. Following the live webcasts, archived
replays will be available on the Company's website.
About Akero Therapeutics
Akero is a cardio-metabolic
NASH company dedicated to reversing the escalating NASH epidemic by
developing pioneering medicines designed to restore metabolic
balance and improve overall health of NASH patients. The Company's
lead product candidate, efruxifermin, has been evaluated in a
16-week Phase 2a clinical trial, the BALANCED study. Akero
Therapeutics is headquartered in South
San Francisco, CA. For more information, please visit
www.akerotx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-upcoming-conferences-in-november-301157248.html
SOURCE Akero Therapeutics, Inc.